Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Escherichia coli strain Nissle 1917 (EcN) is a non-pathogenic, Gram-negative probiotic bacterium that has been used for over a century to treat various gastrointestinal disorders. Originally isolated by Alfred Nissle in 1917, this strain is unique because it lacks common virulence factors and instead possesses fitness factors that allow it to outcompete pathogenic bacteria in the human gut (Wassenaar, 2016). EcN functions by strengthening the intestinal epithelial barrier through the upregulation of tight junction proteins and by inducing the production of antimicrobial peptides like human beta-defensin 2 (Altenhoefer et al., 2004). It also modulates the host immune system by shifting the cytokine balance toward an anti-inflammatory profile, which is particularly beneficial in conditions like ulcerative colitis (Schultz, 2008). In clinical practice, EcN is most notably used for the maintenance of remission in ulcerative colitis, where its efficacy is comparable to the standard-of-care drug mesalazine (Kruis et al., 2004). Beyond its role as a direct therapeutic, EcN is increasingly being utilized in synthetic biology as a chassis for engineered probiotics designed to deliver specific drugs or sense metabolic changes within the microbiota (Landry et al., 2018). While generally considered safe and well-tolerated, its use is contraindicated in severely immunocompromised patients due to the risk of systemic translocation and sepsis (Sonnenborn, 2016). As a living therapeutic, its activity is highly dependent on the host's existing microbiota and can be significantly impaired by the administration of broad-spectrum antibiotics.
EcN exerts therapeutic effects through competitive exclusion of pathogens, production of microcins (M and H47), induction of human beta-defensin 2 (hBD-2), and stabilization of the intestinal epithelial barrier via upregulation of tight junction proteins like ZO-1 and occludin (Altenhoefer et al., 2004; Ukena et al., 2007).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli strain Nissle 1917 (EcN).